Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Lexeo Therapeutics logo — Advancing science with curative potential for both cardiovas...

Lexeo Therapeutics

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.

Founded 2018 United States New York, United States 97 employees Post Ipo Equity Total: $280.00M Biotechnology, Health and Wellness +1

General Information

Company Name Lexeo Therapeutics
Founded Year 2018
Location United States New York, United States +1
Founders / Decision Makers
Ronald G. Crystal — Founder, Chief Scientific Advisor & Board Observer Jenny R. Robertson — Chief Legal & Administrative Officer Sandi See Tai — SVP and Clinical Development and Operations R. Nolan Townsend — CEO
Employees 97
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when Lexeo Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Lexeo Therapeutics recently secured a substantial $95 million post-IPO equity round from prominent life sciences investors, affirming strong market confidence in its genetic medicine pipeline. Concurrently, the company is strategically enhancing patient and community engagement through the launch of "The Heart of FA" platform and active participation in rare disease conferences. This dual focus highlights a strategic shift towards broader stakeholder engagement while bolstering financial resources for continued clinical advancement.

Signal Types
Funding Product Launch Community Engagement
Strategic Labels
Post-IPO Funding Patient Engagement Rare Disease Focus
Next Move: Clinical Trials
·
Impact: 8/10
·
Ideal For: Public Market Biotech Funds — Late-Stage Gene Therapy

About Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based biotechnology startup that is making waves in the field of genetic medicines. The company is on a mission to revolutionize healthcare by leveraging cutting-edge science to change the way diseases are treated. Its focus areas include cardiovascular and APOE4 associated Alzheimer's disease. By collaborating with leading institutions such as Weill Cornell Medicine and the University of California San Diego, Lexeo Therapeutics has been able to advance its pipeline through a stepwise development approach, utilizing early proof-of-concept functional and biomarker data. The startup, established in 2018, has garnered significant attention from investors and recently secured a substantial $95.00M Post-IPO Equity investment on 11 March 2024. This round of funding was backed by prominent investors including Novo Holdings, RA Capital Management, Adage Capital Management, Braidwell, Eventide Asset Management, and Surveyor Capital, further solidifying Lexeo Therapeutics' position in the industry. With a team of experts boasting extensive experience in genetic medicines, rare disease drug development, manufacturing, and commercialization, Lexeo Therapeutics is well-positioned to drive innovations in the biotechnology sector and potentially bring curative treatments to patients in need. For more information, you can visit their website at www.lexeotx.com.

Taxonomy: genetic medicine, clinical-stage, gene therapy, rare diseases, cardiovascular diseases, Alzheimer's disease, AAV-mediated therapies, Weill Cornell Medicine, University of California San Diego, New York City, research collaboration, commercialization, preclinical pipeline, innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $95.00M 6
Novo Holdings RA Capital Management Adage Capital Management Braidwell Eventide Asset Management
Surveyor Capital 		11 Mar 2024
Corporate Round Unknown 1 Sarepta Therapeutics 28 Aug 2023
Series B $100.00M 3
Janus Handerson Omega Funds
Gray’s Creek Capital Partners 		09 Sep 2021
Series A $85.00M - 07 Jan 2021

Latest News

View All
FDA reversals leave investors worrying about the fates of other experimental drugs — Cnbc
FDA reversals leave investors worrying about the fates of other experimental drugs
Cnbc Mar 06, 2026

Lexeo Therapeutics Alternatives & Competitors

Lexeo Therapeutics vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Compare Lexeo Therapeutics vs Locanabio, Inc.
Lexeo Therapeutics vs
EveryONE Medicines
EveryONE Medicines United States

EveryONE Medicines delivers individualized precision therapeutics customized to the unique genetic m...

9 employees
Biotechnology, Health and Wellness
Lexeo Therapeutics vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Series Unknown
7 employees
Biotechnology, Pharmaceutical
Compare Lexeo Therapeutics vs RiboNova, Inc.
Also compare with: Lexeo Therapeutics vs Alltrna Alltrna

FAQ About Lexeo Therapeutics

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
Lexeo Therapeutics was founded in 2018.
Lexeo Therapeutics is headquartered in New York, United States.
Lexeo Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
Lexeo Therapeutics has approximately 97 employees.
Lexeo Therapeutics has completed 4 funding rounds, raising a total of $280.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Lexeo Therapeutics include Locanabio, Inc., EveryONE Medicines, RiboNova, Inc., Alltrna, Genomenon, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lexeo Therapeutics and Locanabio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lexeo Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy